更多栏目
搜索
China Market Approval Tracker: Mar 2021
储旻华·2021-05-12
PharmaDJ
New Cancer & SLE Drugs Gain Market Approval in China

China Market Approval Tracker: Mar 2021


Writer: Minhua Chu

Editor: Justin Fischer


In March 2021, China NMPA green-lighted three in-licensed kinase inhibitors. Among them were pralsetinib and avapritinib from Blueprint Medicines and CStone, respectively, as well as ripretinib from Deciphera and Zai Lab.


Pralsetinib and avapritinib are the first marketed products from CStone Pharmaceuticals, a Chinese biopharmaceutical company listed on the Hong Kong Stock Exchange. The drugs were granted conditional approval as a second-line treatment for adults with locally advanced and metastatic RET fusion-positive non-small cell lung cancer (NSCLC). The drugs are the first RET inhibitors approved in China. They are also the first drugs approved using real-world data compiled by the Lecheng Administration in Hainan.


The Lecheng Administration (Hainan Boao Lecheng International Medical Tourism Pilot Zone Administration) was established in August 2019 in accordance with regulations issued by the State Council. Following a special review procedure, this designated area on the southern Chinese island of Hainan permits the use of drugs and devices that are not yet licensed in the rest of China but have been approved overseas. 


In 2019, a clinical real-world data application pilot was launched in Lecheng. Pratinib arrived in Lecheng shortly after being approved in the US in September 2020. The real-world study results in the Lecheng Administration complement the drug's clinical trial results, providing a valuable aid in regulatory review. This breakthrough reflects a new way of thinking about how we regulate drugs, said Siyuan Zhou, deputy director of the Center for Drug Evaluation (CDE), NMPA.


Telitacicept, an innovative drug from RemeGen also got market approval. The drug was developed to treat active, autoantibody-positive systemic lupus erythematosus (SLE) adult patients who still have high disease activity after standard care. Telitacicept is a novel recombinant TACI-Fc (transmembrane activator and calcium modulator and cyclophilin ligand interactor) fusion protein. It works by binding to the cell-signaling molecules BLyS (B lymphocyte stimulator) and APRIL (a proliferation-inducing ligand).



Two Chinese biotech companies submitted their first New Drug Applications (NDA) as well.


Everest Medicines acquired from Tetraphase Pharmaceuticals the rights to develop and commercialize eravacycline in the Greater China, South Korea and selected Southeast Asia markets. Eravacycline is a fully synthetic tetracycline-class antibiotic indicated for the treatment of complicated intra-abdominal infections (cIAI). It is already marketed in the US and Europe under the brand Xerava.


Also, BeyondSpring announced that it has simultaneously submitted NDAs to the US FDA and the China NMPA for its new drug, plinabulin. The drug's indication is severe neutropenia (CIN). Derived from natural seaweed, plinabulin is a guanine nucleotide exchange factor (GEF-H1) activator, not a G-CSF analog. The molecule can reduce the occurrence of early CIN by reversing the formation of chemotherapy-induced neutrophil blockade in the bone marrow by keeping neutrophil levels within the normal range. The mechanism of action is different from that of G-CSF.



文章关键字: systemic lupus erythematosus (SLE) Cancer NMPA Blueprint Medicines Cstone Deciphera Zai Lab Pralsetinib avapritinib NSCLC The Lecheng Administration CDE Everest Medicines
3586
谁阅读了此文章?
回复评论0
登录后回复评论,不超过1024个字(当前剩余字数:1024)
储旻华 个人用户

热衷收罗医药圈从研发到上市的各种“八卦”,然后基于事实和数据加以分析

联系方式

联系电话

电子邮箱

chu.minhua@pharmadj.com

公司名称

研发客

公司网站

公司地址

进入主页
Copyright © 2016-2021 研发客.All Rights Reserved.   建议反馈: Support@PharmaDJ.com   备案/许可证编号:沪ICP备17054709号-1   联系电话:021 - 88194359
关于研发客 | 加入会员 | 联系我们| 知识产权声明